Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $51.00 at Scotiabank

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) had its price target cut by analysts at Scotiabank from $52.00 to $51.00 in a research report issued on Monday,Benzinga reports. The firm currently has a "sector outperform" rating on the biotechnology company's stock.

A number of other brokerages have also recently commented on RCKT. Chardan Capital dropped their price target on shares of Rocket Pharmaceuticals from $54.00 to $45.00 and set a "buy" rating on the stock in a research note on Friday. Needham & Company LLC restated a "buy" rating and set a $42.00 price target on shares of Rocket Pharmaceuticals in a research note on Wednesday, April 9th. The Goldman Sachs Group dropped their price target on shares of Rocket Pharmaceuticals from $15.00 to $13.00 and set a "neutral" rating on the stock in a research note on Friday. JPMorgan Chase & Co. dropped their price target on shares of Rocket Pharmaceuticals from $45.00 to $44.00 and set an "overweight" rating on the stock in a research note on Friday. Finally, BMO Capital Markets initiated coverage on shares of Rocket Pharmaceuticals in a research note on Wednesday, March 12th. They set an "outperform" rating and a $50.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $40.82.

Rocket Pharmaceuticals Stock Up 3.5%

Shares of RCKT traded up $0.25 on Monday, reaching $7.24. The company's stock had a trading volume of 1,164,489 shares, compared to its average volume of 1,415,204. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06. Rocket Pharmaceuticals has a twelve month low of $4.55 and a twelve month high of $26.98. The stock has a market capitalization of $772.60 million, a PE ratio of -2.62 and a beta of 1.02. The firm has a fifty day moving average of $7.15 and a 200-day moving average of $10.60.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.03. During the same quarter in the prior year, the company earned ($0.66) earnings per share. Equities analysts predict that Rocket Pharmaceuticals will post -2.83 EPS for the current year.

Insider Activity

In other Rocket Pharmaceuticals news, insider Kinnari Patel bought 21,099 shares of the firm's stock in a transaction that occurred on Wednesday, April 9th. The shares were bought at an average price of $4.70 per share, for a total transaction of $99,165.30. Following the transaction, the insider now directly owns 26,774 shares in the company, valued at $125,837.80. This trade represents a 371.79% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Aaron Ondrey sold 7,489 shares of the firm's stock in a transaction on Friday, April 4th. The stock was sold at an average price of $5.29, for a total transaction of $39,616.81. Following the completion of the sale, the chief financial officer now directly owns 129,650 shares in the company, valued at approximately $685,848.50. This trade represents a 5.46% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 28.50% of the company's stock.

Institutional Investors Weigh In On Rocket Pharmaceuticals

A number of large investors have recently modified their holdings of RCKT. Covestor Ltd boosted its stake in Rocket Pharmaceuticals by 33,166.7% during the fourth quarter. Covestor Ltd now owns 1,996 shares of the biotechnology company's stock worth $25,000 after acquiring an additional 1,990 shares in the last quarter. Signaturefd LLC boosted its stake in Rocket Pharmaceuticals by 319.8% during the fourth quarter. Signaturefd LLC now owns 4,916 shares of the biotechnology company's stock worth $62,000 after acquiring an additional 3,745 shares in the last quarter. Harbour Investments Inc. boosted its stake in Rocket Pharmaceuticals by 51.9% during the fourth quarter. Harbour Investments Inc. now owns 5,385 shares of the biotechnology company's stock worth $68,000 after acquiring an additional 1,840 shares in the last quarter. KBC Group NV boosted its stake in Rocket Pharmaceuticals by 159.6% during the fourth quarter. KBC Group NV now owns 5,475 shares of the biotechnology company's stock worth $69,000 after acquiring an additional 3,366 shares in the last quarter. Finally, Virtus ETF Advisers LLC boosted its stake in Rocket Pharmaceuticals by 40.4% during the fourth quarter. Virtus ETF Advisers LLC now owns 5,656 shares of the biotechnology company's stock worth $71,000 after acquiring an additional 1,628 shares in the last quarter. Institutional investors own 98.39% of the company's stock.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.